233 related articles for article (PubMed ID: 22959982)
21. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice.
Rappazzo CG; Watkins HC; Guarino CM; Chau A; Lopez JL; DeLisa MP; Leifer CA; Whittaker GR; Putnam D
Vaccine; 2016 Mar; 34(10):1252-8. PubMed ID: 26827663
[TBL] [Abstract][Full Text] [Related]
22. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
[TBL] [Abstract][Full Text] [Related]
23. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
[TBL] [Abstract][Full Text] [Related]
24. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.
Zhao G; Lin Y; Du L; Guan J; Sun S; Sui H; Kou Z; Chan CC; Guo Y; Jiang S; Zheng BJ; Zhou Y
Virol J; 2010 Jan; 7():9. PubMed ID: 20082709
[TBL] [Abstract][Full Text] [Related]
25. Influenza virus M2e with additional cysteine residues shows enhanced immunogenicity and protection against lethal virus challenge.
Kaminaka K; Matsuda J; Nozaki C
Viral Immunol; 2013 Aug; 26(4):291-5. PubMed ID: 23941675
[TBL] [Abstract][Full Text] [Related]
26. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
[TBL] [Abstract][Full Text] [Related]
27. Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes.
Wibowo N; Hughes FK; Fairmaid EJ; Lua LH; Brown LE; Middelberg AP
Vaccine; 2014 Jun; 32(29):3651-5. PubMed ID: 24795225
[TBL] [Abstract][Full Text] [Related]
28. A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate.
Zeng W; Tan AC; Horrocks K; Jackson DC
Vaccine; 2015 Jul; 33(30):3526-32. PubMed ID: 26049002
[TBL] [Abstract][Full Text] [Related]
29. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.
Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP
Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588
[TBL] [Abstract][Full Text] [Related]
30. Development of a novel dual-domain nanoparticle antigen construct for universal influenza vaccine.
Ni Y; Guo J; Turner D; Tizard I
Vaccine; 2017 Dec; 35(50):7026-7032. PubMed ID: 29102171
[TBL] [Abstract][Full Text] [Related]
31. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
[TBL] [Abstract][Full Text] [Related]
32. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e.
Li R; Lim A; Ow ST; Phoon MC; Locht C; Chow VT; Alonso S
Vaccine; 2011 Jul; 29(33):5502-11. PubMed ID: 21624415
[TBL] [Abstract][Full Text] [Related]
33. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
[TBL] [Abstract][Full Text] [Related]
34. Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens.
Zhang X; Liu M; Liu C; Du J; Shi W; Sun E; Li H; Li J; Zhang Y
Intervirology; 2011; 54(5):290-9. PubMed ID: 21228535
[TBL] [Abstract][Full Text] [Related]
35. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.
Denis J; Acosta-Ramirez E; Zhao Y; Hamelin ME; Koukavica I; Baz M; Abed Y; Savard C; Pare C; Lopez Macias C; Boivin G; Leclerc D
Vaccine; 2008 Jun; 26(27-28):3395-403. PubMed ID: 18511159
[TBL] [Abstract][Full Text] [Related]
36. M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection.
Tao W; Gill HS
Vaccine; 2015 May; 33(20):2307-15. PubMed ID: 25842219
[TBL] [Abstract][Full Text] [Related]
37. Self-assembly polymerization enhances the immunogenicity of influenza M2e peptide.
Zou P; Li Y; Huang J; Wu F
Microbes Infect; 2017 Dec; 19(12):648-654. PubMed ID: 28939356
[TBL] [Abstract][Full Text] [Related]
38. Universal influenza A vaccine: optimization of M2-based constructs.
De Filette M; Min Jou W; Birkett A; Lyons K; Schultz B; Tonkyro A; Resch S; Fiers W
Virology; 2005 Jun; 337(1):149-61. PubMed ID: 15914228
[TBL] [Abstract][Full Text] [Related]
39. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection.
Zou P; Liu W; Chen YH
Int Immunopharmacol; 2005 Apr; 5(4):631-5. PubMed ID: 15710332
[TBL] [Abstract][Full Text] [Related]
40. A "universal" human influenza A vaccine.
Fiers W; De Filette M; Birkett A; Neirynck S; Min Jou W
Virus Res; 2004 Jul; 103(1-2):173-6. PubMed ID: 15163506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
